

# Resource Summary Report

Generated by [RRID](#) on Sep 11, 2026

## Phospho-c-Raf (Ser259) Antibody

RRID:AB\_330759

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 9421, RRID:AB\_330759

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_330759](http://antibodyregistry.org/AB_330759)

**Proper Citation:** Cell Signaling Technology Cat# 9421, RRID:AB\_330759

**Target Antigen:** Phospho-c-Raf (Ser259)

**Host Organism:** rabbit

**Clonality:** polyclonal

**Comments:** Applications: W, IP. Consolidation on 10/2018: AB\_10078658, AB\_10836482, AB\_330759.

**Antibody Name:** Phospho-c-Raf (Ser259) Antibody

**Description:** This polyclonal targets Phospho-c-Raf (Ser259)

**Target Organism:** rat, xenopusamphibian, h, m, mouse, r, x, human

**Antibody ID:** AB\_330759

**Vendor:** Cell Signaling Technology

**Catalog Number:** 9421

**Record Creation Time:** 20231110T081401+0000

**Record Last Update:** 20260829T221012+0000

---

### Ratings and Alerts

No rating or validation information has been found for Phospho-c-Raf (Ser259) Antibody.

No alerts have been found for Phospho-c-Raf (Ser259) Antibody.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 12 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Kondo Y, et al. (2026) Mechanism of MEK1 phosphorylation by the N-terminal acidic motif-mediated asymmetric BRAF dimer. Molecular cell.

Bajikar SS, et al. (2024) Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels. Human molecular genetics.

Wang Y, et al. (2023) Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models. Cell death discovery, 9(1), 60.

Qian F, et al. (2023) Activation of GPR44 decreases severity of myeloid leukemia via specific targeting of leukemia initiating stem cells. Cell reports, 42(7), 112794.

Zhang K, et al. (2023) Targeting GPR65 alleviates hepatic inflammation and fibrosis by suppressing the JNK and NF- $\kappa$ B pathways. Military Medical Research, 10(1), 56.

Xia Y, et al. (2023) Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP. European journal of pharmacology, 961, 176157.

Wong S, et al. (2023) RAF1 deficiency causes a lethal syndrome that underscores RTK signaling during embryogenesis. EMBO molecular medicine, 15(5), e17078.

Gao X, et al. (2022) Lyso-PAF, a biologically inactive phospholipid, contributes to RAF1 activation. Molecular cell, 82(11), 1992.

Joshi S, et al. (2021) Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. Communications biology, 4(1), 1333.

Liao S, et al. (2019) Tanshinol borneol ester, a novel synthetic small molecule angiogenesis stimulator inspired by botanical formulations for angina pectoris. British journal of pharmacology, 176(17), 3143.

Lian X, et al. (2019) The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. British journal of pharmacology, 176(5), 711.

Sulahian R, et al. (2019) Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell reports, 29(1), 118.